Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kokudo, N.
Right arrow Articles by Aiba, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kokudo, N.
Right arrow Articles by Aiba, K.

Annals of Surgical Oncology, Vol 5, Issue 8 706-712, Copyright © 1998 by Society of Surgical Oncology

ARTICLES

Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases

N. Kokudo, M. Seki, H. Ohta, K. Azekura, M. Ueno, T. Sato, A. Moroguchi, T. Matsubara, T. Takahashi, T. Nakajima and K. Aiba
Department of Surgery, Cancer Institute Hospital, Tokyo, Japan.

BACKGROUND: Although the survival benefit of hepatic resection for colorectal metastasis has been established, some controversy remains regarding the significance of adjuvant chemotherapy after hepatic resection. METHODS: One hundred thirty-two consecutive patients who had liver resection for colorectal metastasis at our hospital between 1980 and 1997 were studied. After curative hepatic resection, 37 patients underwent systemic chemotherapy, administered orally or intravenously, and 38 patients underwent regional chemotherapy, given intra-arterially or intraportally. Forty patients had no adjuvant chemotherapy. The chemotherapeutic agents used for oral administration were uracil and Tegafur or Tegafur alone. Mitomycin C (MMC) or 5-FU was used for IV chemotherapy. Combinations of 5-FU/leucovorin or MMC/5-FU (doxorubicin) were used for regional chemotherapy. Univariate and multivariate analyses were applied to test the significance of adjuvant chemotherapy for patient survival or disease-free survival. RESULTS: Overall 5-year survival was 42.2% (95% CL: 31.2%, 53.2%). Among the possible prognostic factors studied, univariate analysis showed a significant difference in survival based on the number of tumors and lymph node metastases in the hepatic hilum. There was a significant difference in disease-free survival based on adjuvant chemotherapy and lymph node metastasis. The multivariate analysis for patient survival selected four prognostic factors (P < .05), including adjuvant chemotherapy, lymph node metastasis, disease-free interval, and tumor size. The multivariate analysis for disease-free survival selected adjuvant chemotherapy, lymph node metastasis, and disease-free interval as significant factors. The most common recurrence site was remnant liver, regardless of adjuvant chemotherapy. CONCLUSIONS: Adjuvant chemotherapy significantly improved survival and disease-free survival after hepatic resection for colorectal metastases. It did not decrease recurrence rate in the remnant liver.


This article has been cited by other articles:


Home page
 JCOHome page
N. Kokudo, K. Hasegawa, and M. Makuuchi
Control Arm for Surgery Alone Is Needed but Difficult to Obtain in Randomized Trials for Adjuvant Chemotherapy After Liver Resection for Colorectal Metastases
J. Clin. Oncol., April 1, 2007; 25(10): 1299 - 1300.
[Full Text] [PDF]

Home page
 JCOHome page
K. K. Herfarth, J. Debus, F. Lohr, M. L. Bahner, B. Rhein, P. Fritz, A. Hoss, W. Schlegel, and M. F. Wannenmacher
Stereotactic Single-Dose Radiation Therapy of Liver Tumors: Results of a Phase I/II Trial
J. Clin. Oncol., January 1, 2001; 19(1): 164 - 170.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society of Surgical Oncology.